Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NeoLumina
Bedminster, New Jersey, United Statesneolumina.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
NeoLumina Bioscience is a biotechnology company specializing in the development of next-generation radiopharmaceuticals for the treatment of cancer. The company utilizes a theranostic approach, combining diagnostic imaging with targeted radionuclide therapy to improve patient outcomes. Its lead program, NLM-001, is a Lutetium-177 labeled radioligand targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer. NeoLumina aims to overcome the limitations of current radiotherapies by optimizing ligand design for better tumor uptake and reduced off-target toxicity. The company is led by industry veterans with significant experience in radiopharmaceutical development and oncology.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalSmall molecule
- Industry
- Biotech
Beyond the preview
Go deeper on NeoLumina.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NeoLumina.